Darwin AG: new projects in the field of medical genetics

Munich, October 21, 2025 (pta015/21.10.2025/10:00 UTC+2)

The subsidiaries of Darwin AG (ISIN DE000A3C35W0), namely Novogenia GmbH and HLN Genetik GmbH, both based in Austria, have achieved significant project successes in the field of medical genetics:

HLN Genetik was able to secure a major customer contract in the field of medical genetics, which is expected to increase the company's revenue by over 50% in the coming fiscal year. Within the new partnership, HLN Genetik is collaborating with a major Austrian clinic. HLN's newly formed management team, which was established in January, has thus achieved a groundbreaking sales success. Key to the collaboration are significantly shorter processing times compared to competitors while maintaining the highest quality standards.

Novogenia's genetic laboratory has meanwhile completed its certification work for CLIA (Clinical Laboratory Improvement Amendments) certification. This provides Novogenia with the formal requirements to offer medical genetic analyses for the US market. This is a key building block in the expansion of the cooperation with REVIV and 10X Health into the field of medical genetics.

"This sales breakthrough and successful certification show that we are continuously demonstrating our competitiveness in the field of medical genetics" analyzes CEO Dr. Daniel Wallerstorfer. "These milestones confirm our growth trend beyond 2025," the company founder continues.

About Darwin AG

The 'Darwin Group' (i.e., Darwin AG including its subsidiaries and sub-subsidiaries), headquartered in Munich (Germany), is a European biotechnology company specializing in human genetics. The genetic analyses carried out in its own laboratory are used in the diagnosis, therapy, and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists, or fitness trainers, and helps to ensure the most optimal treatment or care for the patient or client by analyzing their respective genetic predisposition. In addition, Darwin invests in innovative companies in the fields of biotech, healthcare, and life sciences.

(end)

Emitter:	Darwin AG Brienner Straße 7 80333 München Germany
Contact Person:	Daniel Wallerstorfer
Phone:	+49 89 20 500 450
E-Mail:	investor.relations@darwin-biotech.com
Website:	www.darwin-biotech.com
ISIN(s):	DE000A3C35W0 (Share)
Stock Exchange(s):	Free Market in Frankfurt, Munich (m:access)